Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Nat Med ; 27(10): 1701-1711, 2021 10.
Article in English | MEDLINE | ID: mdl-34608334

ABSTRACT

Spinal muscular atrophy type 1 (SMA1) is a debilitating neurodegenerative disease resulting from survival motor neuron 1 gene (SMN1) deletion/mutation. Onasemnogene abeparvovec (formerly AVXS-101) is a gene therapy that restores SMN production via one-time systemic administration. The present study demonstrates widespread biodistribution of vector genomes and transgenes throughout the central nervous system (CNS) and peripheral organs, after intravenous administration of an AAV9-mediated gene therapy. Two symptomatic infants with SMA1 enrolled in phase III studies received onasemnogene abeparvovec. Both patients died of respiratory complications unrelated to onasemnogene abeparvovec. One patient had improved motor function and the other died shortly after administration before appreciable clinical benefit could be observed. In both patients, onasemnogene abeparvovec DNA and messenger RNA distribution were widespread among peripheral organs and in the CNS. The greatest concentration of vector genomes was detected in the liver, with an increase over that detected in CNS tissues of 300-1,000-fold. SMN protein, which was low in an untreated SMA1 control, was clearly detectable in motor neurons, brain, skeletal muscle and multiple peripheral organs in treated patients. These data support the fact that onasemnogene abeparvovec has effective distribution, transduction and expression throughout the CNS after intravenous administration and restores SMN expression in humans.


Subject(s)
Biological Products/adverse effects , Genetic Therapy/adverse effects , Recombinant Fusion Proteins/adverse effects , Spinal Muscular Atrophies of Childhood/therapy , Survival of Motor Neuron 1 Protein/genetics , Autopsy , Biological Products/administration & dosage , DNA/genetics , Female , Genetic Vectors/administration & dosage , Genetic Vectors/adverse effects , Genetic Vectors/genetics , Humans , Infant , Infant, Newborn , Male , Motor Neurons/drug effects , Motor Neurons/pathology , RNA, Messenger/genetics , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/genetics , Spinal Muscular Atrophies of Childhood/genetics , Spinal Muscular Atrophies of Childhood/mortality , Spinal Muscular Atrophies of Childhood/pathology , Tissue Distribution/drug effects
2.
PLoS One ; 10(3): e0121738, 2015.
Article in English | MEDLINE | ID: mdl-25815836

ABSTRACT

The choroid plexus (ChP) epithelium is a multifunctional tissue found in the ventricles of the brain. The major function of the ChP epithelium is to produce cerebrospinal fluid (CSF) that bathes and nourishes the central nervous system (CNS). In addition to the CSF, ChP epithelial cells (CPECs) produce and secrete numerous neurotrophic factors that support brain homeostasis, such as adult hippocampal neurogenesis. Accordingly, damage and dysfunction to CPECs are thought to accelerate and intensify multiple disease phenotypes, and CPEC regeneration would represent a potential therapeutic approach for these diseases. However, previous reports suggest that CPECs rarely divide, although this has not been extensively studied in response to extrinsic factors. Utilizing a cell-cycle reporter mouse line and live cell imaging, we identified scratch injury and the growth factors insulin-like growth factor 1 (IGF-1) and epidermal growth factor (EGF) as extrinsic cues that promote increased CPEC expansion in vitro. Furthermore, we found that IGF-1 and EGF treatment enhances scratch injury-induced proliferation. Finally, we established whole tissue explant cultures and observed that IGF-1 and EGF promote CPEC division within the intact ChP epithelium. We conclude that although CPECs normally have a slow turnover rate, they expand in response to external stimuli such as injury and/or growth factors, which provides a potential avenue for enhancing ChP function after brain injury or neurodegeneration.


Subject(s)
Cell Culture Techniques/methods , Choroid Plexus/cytology , Epithelial Cells/cytology , Tissue Culture Techniques/methods , Animals , Cell Cycle/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Epidermal Growth Factor/pharmacology , Insulin-Like Growth Factor I/pharmacology , Mice
3.
Curr Stem Cell Res Ther ; 6(4): 327-38, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21466483

ABSTRACT

The plasticity of neural stem/progenitor cells allows a variety of different responses to many environmental cues. In the past decade, significant research has gone into understanding the regulation of neural stem/progenitor cell properties, because of their promise for cell replacement therapies in adult neurological diseases. Both endogenous and grafted neural stem/progenitor cells are known to have the ability to migrate long distances to lesioned sites after brain injury and differentiate into new neurons. Several chemokines and growth factors, including stromal cell-derived factor-1 and vascular endothelial growth factor, have been shown to stimulate the proliferation, differentiation, and migration of neural stem/progenitor cells, and investigators have now begun to identify the critical downstream effectors and signaling mechanisms that regulate these processes. Both our own lab and others have shown that the extracellular matrix and matrix remodeling factors play a critical role in directing cell differentiation and migration of adult neural stem/progenitor cells within injured sites. Identification of these and other molecular pathways involved in stem cell homing into ischemic areas is vital for the development of new treatments. To ensure the best functional recovery, regenerative therapy may require the application of a combination approach that includes cell replacement, trophic support, and neural protection. Here we review the current state of our knowledge about endogenous adult and exogenous neural stem/progenitor cells as potential therapeutic agents for central nervous system injuries.


Subject(s)
Adult Stem Cells/transplantation , Neural Stem Cells/transplantation , Stroke/pathology , Stroke/therapy , Adult Stem Cells/physiology , Brain Injuries/therapy , Cell Communication , Cell Differentiation , Cell Movement , Cell Proliferation , Extracellular Matrix/physiology , Gap Junctions/physiology , Genetic Therapy/methods , Humans , Induced Pluripotent Stem Cells/physiology , Induced Pluripotent Stem Cells/transplantation , Neural Stem Cells/physiology , Neurogenesis , Stem Cell Niche , Stem Cell Transplantation
4.
Nature ; 472(7342): 221-5, 2011 Apr 14.
Article in English | MEDLINE | ID: mdl-21346760

ABSTRACT

Hutchinson-Gilford progeria syndrome (HGPS) is a rare and fatal human premature ageing disease, characterized by premature arteriosclerosis and degeneration of vascular smooth muscle cells (SMCs). HGPS is caused by a single point mutation in the lamin A (LMNA) gene, resulting in the generation of progerin, a truncated splicing mutant of lamin A. Accumulation of progerin leads to various ageing-associated nuclear defects including disorganization of nuclear lamina and loss of heterochromatin. Here we report the generation of induced pluripotent stem cells (iPSCs) from fibroblasts obtained from patients with HGPS. HGPS-iPSCs show absence of progerin, and more importantly, lack the nuclear envelope and epigenetic alterations normally associated with premature ageing. Upon differentiation of HGPS-iPSCs, progerin and its ageing-associated phenotypic consequences are restored. Specifically, directed differentiation of HGPS-iPSCs to SMCs leads to the appearance of premature senescence phenotypes associated with vascular ageing. Additionally, our studies identify DNA-dependent protein kinase catalytic subunit (DNAPKcs, also known as PRKDC) as a downstream target of progerin. The absence of nuclear DNAPK holoenzyme correlates with premature as well as physiological ageing. Because progerin also accumulates during physiological ageing, our results provide an in vitro iPSC-based model to study the pathogenesis of human premature and physiological vascular ageing.


Subject(s)
Induced Pluripotent Stem Cells/pathology , Aging/metabolism , Aging/pathology , Aging/physiology , Aging, Premature/genetics , Aging, Premature/pathology , Aging, Premature/physiopathology , Calcium-Binding Proteins/analysis , Cell Differentiation , Cell Line , Cellular Reprogramming , Cellular Senescence , DNA-Activated Protein Kinase/metabolism , Epigenesis, Genetic , Fibroblasts/pathology , Holoenzymes/metabolism , Humans , Induced Pluripotent Stem Cells/metabolism , Lamin Type A , Microfilament Proteins/analysis , Models, Biological , Muscle, Smooth, Vascular/pathology , Nuclear Envelope/pathology , Nuclear Proteins/analysis , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Phenotype , Progeria/genetics , Progeria/pathology , Progeria/physiopathology , Protein Precursors/analysis , Protein Precursors/genetics , Protein Precursors/metabolism , Substrate Specificity , Calponins
5.
PLoS Genet ; 6(4): e1000898, 2010 Apr 08.
Article in English | MEDLINE | ID: mdl-20386739

ABSTRACT

Fragile X syndrome (FXS), the most common form of inherited mental retardation, is caused by the loss of functional fragile X mental retardation protein (FMRP). FMRP is an RNA-binding protein that can regulate the translation of specific mRNAs. Adult neurogenesis, a process considered important for neuroplasticity and memory, is regulated at multiple molecular levels. In this study, we investigated whether Fmrp deficiency affects adult neurogenesis. We show that in a mouse model of fragile X syndrome, adult neurogenesis is indeed altered. The loss of Fmrp increases the proliferation and alters the fate specification of adult neural progenitor/stem cells (aNPCs). We demonstrate that Fmrp regulates the protein expression of several components critical for aNPC function, including CDK4 and GSK3beta. Dysregulation of GSK3beta led to reduced Wnt signaling pathway activity, which altered the expression of neurogenin1 and the fate specification of aNPCs. These data unveil a novel regulatory role for Fmrp and translational regulation in adult neurogenesis.


Subject(s)
Cell Differentiation/genetics , Cell Proliferation , Fragile X Mental Retardation Protein/genetics , Gene Expression Regulation , Neurogenesis , Stem Cells/cytology , Animals , Cyclin-Dependent Kinase 4/genetics , Cyclin-Dependent Kinase 4/metabolism , Fragile X Syndrome/genetics , Fragile X Syndrome/metabolism , Glycogen Synthase Kinase 3/genetics , Glycogen Synthase Kinase 3/metabolism , Glycogen Synthase Kinase 3 beta , Mice , Mice, Knockout , Neurons/metabolism , Stem Cells/metabolism
6.
Stem Cells ; 26(12): 3139-49, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18818437

ABSTRACT

Adult neurogenesis is regulated by both intrinsic programs and extrinsic stimuli. The enhanced proliferation of adult neural stem/progenitor cells (aNPCs) in the subventricular zone and the migration of neuroblasts toward the ischemic region in adult brains present a unique challenge as well as an opportunity to understand the molecular mechanisms underlying the extrinsic cue-induced neurogenic responses. Matrix metalloproteinases (MMPs) are a family of proteinases known to play a role in extracellular matrix remodeling and cell migration. However, their presence in aNPCs and their potential function in injury-induced aNPC migration remain largely unexplored. Here we demonstrate that in response to two injury-induced chemokines, stromal cell-derived factor 1 (SDF-1) and vascular endothelial growth factor, aNPCs differentiated into migratory cells that expressed increased levels of MMP-3 and MMP-9. Whereas differentiated neuroblasts and a subpopulation of astrocytes migrated toward the chemokines, undifferentiated progenitors did not migrate. Blocking the expression of MMP-3 or MMP-9 in aNPCs interfered with both the differentiation of aNPCs and chemokine-induced cell migration. Thus, endogenous MMPs expressed by aNPCs are important for mediating their neurogenic response to extrinsic signals.


Subject(s)
Chemokines/metabolism , Matrix Metalloproteinase 3/metabolism , Matrix Metalloproteinase 9/metabolism , Neurons/metabolism , Stem Cells/metabolism , Animals , Cell Differentiation , Cell Movement , Cells, Cultured , Humans , Infarction, Middle Cerebral Artery/pathology , Lentivirus/metabolism , Mice , Recombinant Proteins/metabolism , Stem Cells/cytology , Vascular Endothelial Growth Factor A/metabolism
7.
J Biol Chem ; 283(41): 27644-27652, 2008 Oct 10.
Article in English | MEDLINE | ID: mdl-18689796

ABSTRACT

Whether and how mechanisms intrinsic to stem cells modulate their proliferation and differentiation are two central questions in stem cell biology. Although exogenous basic fibroblast growth factor 2 (FGF-2/Fgf-2) is commonly used to expand adult neural stem/progenitor cells (NSPCs) in vitro, we do not yet understand the functional significance or the molecular regulation of Fgf-2 expressed endogenously by adult NSPCs. We previously demonstrated that methylated CpG binding protein 1 (MBD1/Mbd1) is a transcriptional repressor of Fgf-2 and is enriched in adult brains. Mbd1 deficiency in mice selectively affected adult neurogenesis and the differentiation of NSPCs. Here we show that an Mbd1 and DNA methylation-mediated epigenetic mechanism regulated the expression of stem cell mitogen Fgf-2 in adult NSPCs. Mbd1 bound to the Fgf-2 promoter and regulates its expression in adult NSPCs. In the absence of functional Mbd1, the Fgf-2 promoter was hypomethylated, and treatment with a DNA methylation inhibitor resulted in increased Fgf-2 expression in adult NSPCs. We further demonstrated that both acute knockdown of Mbd1 or overexpression of Fgf-2 in adult NSPCs inhibited their neuronal differentiation, which could be responsible for the neurogenic deficits observed in Mbd1-deficient mice. These data indicate that intrinsic epigenetic mechanisms play critical roles in the regulation of adult NSPC functions.


Subject(s)
DNA-Binding Proteins/metabolism , Epigenesis, Genetic/physiology , Fibroblast Growth Factor 2/biosynthesis , Mitogens/biosynthesis , Neurons/metabolism , Adult Stem Cells , Animals , Cell Differentiation/physiology , Cell Proliferation , Cells, Cultured , DNA Methylation , DNA-Binding Proteins/genetics , Fibroblast Growth Factor 2/genetics , Mice , Mice, Knockout , Mitogens/genetics , Neurons/cytology , Promoter Regions, Genetic/physiology , Protein Binding/physiology , Rats
8.
Neurobiol Dis ; 27(1): 77-89, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17532643

ABSTRACT

It is well known that Rett Syndrome, a severe postnatal childhood neurological disorder, is mostly caused by mutations in the MECP2 gene. However, how deficiencies in MeCP2 contribute to the neurological dysfunction of Rett Syndrome is not clear. We aimed to resolve the role of MeCP2 epigenetic regulation in postnatal brain development in an Mecp2-deficient mouse model. We found that, while Mecp2 was not critical for the production of immature neurons in the dentate gyrus (DG) of the hippocampus, the newly generated neurons exhibited pronounced deficits in neuronal maturation, including delayed transition into a more mature stage, altered expression of presynaptic proteins and reduced dendritic spine density. Furthermore, analysis of gene expression profiles of isolated DG granule neurons revealed abnormal expression levels of a number of genes previously shown to be important for synaptogenesis. Our studies suggest that MeCP2 plays a central role in neuronal maturation, which might be mediated through epigenetic control of expression pathways that are instrumental in both dendritic development and synaptogenesis.


Subject(s)
Dentate Gyrus/growth & development , Dentate Gyrus/pathology , Methyl-CpG-Binding Protein 2/genetics , Rett Syndrome/genetics , Rett Syndrome/physiopathology , Animals , Animals, Newborn , Cell Differentiation/physiology , Dendritic Spines/pathology , Dendritic Spines/physiology , Dentate Gyrus/physiopathology , Epigenesis, Genetic/physiology , Gene Expression Regulation, Developmental , Methyl-CpG-Binding Protein 2/deficiency , Methyl-CpG-Binding Protein 2/metabolism , Mice , Mice, Inbred ICR , Mice, Knockout , Neurons/pathology , Neurons/physiology , Neurons/ultrastructure , Presynaptic Terminals/physiology , Rett Syndrome/pathology
9.
Stem Cells Dev ; 15(3): 407-21, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16846377

ABSTRACT

Multipotent neural stem/progenitor cells (NSPCs) can be isolated from many regions of the adult central nervous system (CNS), yet neurogenesis is restricted to the hippocampus and subventricular zone in vivo. Identification of the molecular cues that modulate NSPC fate choice is a prerequisite for their therapeutic applications. Previously, we demonstrated that primary astrocytes isolated from regions with higher neuroplasticity, such as newborn and adult hippocampus and newborn spinal cord, promoted neuronal differentiation of adult NSPCs, whereas astrocytes isolated from the nonneurogenic region of the adult spinal cord inhibited neural differentiation. To identify the factors expressed by these astrocytes that could modulate NSPC differentiation, we performed gene expression profiling analysis using Affymetrix rat genome arrays. Our results demonstrated that these astrocytes had distinct gene expression profiles. We further tested the functional effects of candidate factors that were differentially expressed in neurogenesis-promoting and -inhibiting astrocytes using in vitro NSPC differentiation assays. Our results indicated that two interleukins, IL-1beta and IL-6, and a combination of factors that included these two interleukins could promote NSPC neuronal differentiation, whereas insulin-like growth factor binding protein 6 (IGFBP6) and decorin inhibited neuronal differentiation of adult NSPCs. Our results have provided further evidence to support the ongoing hypothesis that, in adult mammalian brains, astrocytes play critical roles in modulating NSPC differentiation. The finding that cytokines and chemokines expressed by astrocytes could promote NSPC neuronal differentiation may help us to understand how injuries induce neurogenesis in adult brains.


Subject(s)
Astrocytes/cytology , Astrocytes/metabolism , Cell Differentiation , Neurons/cytology , Stem Cells/cytology , Animals , Animals, Newborn , Basic Helix-Loop-Helix Transcription Factors/genetics , Cell Differentiation/drug effects , Cells, Cultured , Cytokines/pharmacology , Gene Expression Profiling , Gene Expression Regulation/drug effects , Humans , Mice , Nerve Tissue Proteins/genetics , Neurons/drug effects , Promoter Regions, Genetic/drug effects , Proteins/metabolism , Rats , Stem Cells/drug effects
10.
Proc Natl Acad Sci U S A ; 100(11): 6777-82, 2003 May 27.
Article in English | MEDLINE | ID: mdl-12748381

ABSTRACT

DNA methylation-mediated epigenetic regulation plays critical roles in regulating mammalian gene expression, but its role in normal brain function is not clear. Methyl-CpG binding protein 1 (MBD1), a member of the methylated DNA-binding protein family, has been shown to bind methylated gene promoters and facilitate transcriptional repression in vitro. Here we report the generation and analysis of MBD1-/- mice. MBD1-/- mice had no detectable developmental defects and appeared healthy throughout life. However, we found that MBD1-/- neural stem cells exhibited reduced neuronal differentiation and increased genomic instability. Furthermore, adult MBD1-/- mice had decreased neurogenesis, impaired spatial learning, and a significant reduction in long-term potentiation in the dentate gyrus of the hippocampus. Our findings indicate that DNA methylation is important in maintaining cellular genomic stability and is crucial for normal neural stem cell and brain functions.


Subject(s)
CpG Islands , DNA-Binding Proteins/genetics , Hippocampus/physiology , Animals , Cell Differentiation , Hippocampus/cytology , Mice , Mice, Knockout , Neurons/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...